Horizon Space Acquisition I Corp. (HSPOF): Entry into a Material Definitive Agreement
Horizon Space Acquisition I Corp. (HSPOF) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EXHIBIT 99.1 Horizon Space Acquisition I Corp. Announces Definitive Business Combination Agreement with ArcheNova Biotech Corp. NEW YORK, NY, October 13, 2026 (Accesswire) – Horizon Space Acquisition I Corp. (“HSPO”) (OTC: HSPOF), a publicly traded special purpose acquisition com
How this was made
The 30-second read
Why it matters
The announcement creates a new public biotech, potentially unlocking shareholder value and providing a vehicle for future capital raises.
Market read
Primary SPAC‑biotech merger news; may affect biotech sector sentiment and OTC market participants.
What to watch
Regulatory approvals for exosome therapies and integration risks could delay value realization.
Background
HSPO is an OTC‑listed special purpose acquisition company that announced a definitive business combination with private biotech ArcheNova, which will result in a Nasdaq‑listed entity.
Ticker impact
HSPO filed an 8‑K announcing a definitive business combination agreement with ArcheNova Biotech, creating a new Nasdaq‑listed public company.
likely upside as market prices in the upcoming Nasdaq listing and biotech pipeline potential
First‑report of a material SPAC‑biotech combination; investors will reassess valuation ahead of the Q1‑2027 closing.
Market effects
Adds a new biotech player to the Nasdaq biotech sector, may boost sector sentiment.
Limited to US OTC and Nasdaq markets; no broader regional effect.
Modest global relevance, primarily biotech investors.
Counterpoint
If the biotech pipeline fails to meet expectations, the SPAC could trade down despite the deal.
Key entities
- SPACHorizon Space Acquisition I Corp.
OTC‑listed SPAC entering a business combination with ArcheNova.
- BiotechArcheNova Biotech Corp.
Private clinical‑stage company focused on MSC‑exosome therapeutics.
